Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection by Niggemann, B. et al.
Research Paper
Mediators of Inflammation 4, 282-288 (1995)
I order to study the time-course of myeloperox-
idase (MPO) and eosinophil cationic protein
(ECP) as parameters for monitoring inflamma-
tion in cystic fibrosis (CF), we investigated ten
patients during both a 14-day intravenous anti-
biotic treatment and a corresponding self control.
Modified Shwachman-Kulczycki score improved
significantly (p < 0.008), C-reactive protein (CRP)
levels decreased significantly (p < 0.05) during
antibiotic treatment, while in the control phase
there were no significant differences. Lung
function parameters did not change significantly
during antibiotic treatment or control phase.
Serum MPO concentration (p < 0.006) and peri-
pheral blood neutrophil granulocyte counts
(p < 0.04) decreased significantly during anti-
biotic treatment, but not during the control
phase. Sentm ECP concentration showed a
tendency to decrease during antibiotic treatment,
but this failed to reach significance. In general,
sputum concentrations of MPO and ECP Were
500- to 1000-fold higher than in serum. However,
neither MPO nor ECP in sputum showed a sig-
nifican variation over time during antibiotic
treatment or control phase. From our data we
conclude that: (1) measurements of MPO, neut-
rophils and CRP in peripheral blood do correlate
with clinical parameters such as the modified
Shwachman-Kulczycki score; (2) neutrophils and
MPO seem to reflect inflammatory changes
induced by antibiotic treatment; (3) eosinophils
may play a role in CF by an enhanced ’releas-
ability’ and (4) Sputum measurements of media-
tors of inflammation cannot be recommended.
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Introduction
Patients with cystic fibrosis (CF) suffer from
chronic Pseudomonas aeruginosa infection and
a dramatic neutrophil recruitment into the lungs.
This results in a proteinase imbalance and a sub-
sequent progressive proteolytic destruction of
lung connective tissue.-
Deterioration of lung
function and parameters of inflammation (e.g., C-
reactive protein CRP) parallels the time-course of
progressive host inflammatory responses to
chronic Pseudomonas aeruginosa infection.
4
Myeloperoxidase (MPO), as a neutrophil gran-
ulocyte-specifi inflammatory mediator, could be
shown to have cytotoxic properties to the lung
epithelium in vitro.5 Other neutrophil granule
products correlate with lung function parameters
and CRP in acute exacerbations in CF.
Eosinophils and their granule proteins play a
major role for chronic inflammation in bronchial
asthma, but there is controversy about the role
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of the eosinophils in CF. While an Austdan
working group saw evidence for an eosinophilic
activation in CF,
7 other authors did not find ele-
vated numbers of eosinophils in post-mortem CF
lungs.
Because there is little information concerning
the role of the inflammatory mediators MPO and
eosinophil cationic protein (ECP) as parameters
for monitoring inflammation in CF patients, we
studied these mediators in serum and sputum
during a 14-day intravenous antibiotic treatment
and a 14-day in-patient control phase and com-
pared them with clinical parameters.
Patients and Methods
Patients: Ten patients (three males, seven
females) aged 14 to 44 years (mean age 24 years)
with cystic fibrosis were enrolled in the study.
Patient data are shown in Table 1. Diagnosis of
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Table 1. Patient data at entry into study
Patient no. Sex Age Weight Height
(years) (kg) (cm)
C-N score Total IgE Atopic
(kU/l)
M 14 28.9 149
2 F 16 37.8 153
3 M 29 65.7 178
4 F 25 49.8 158
5 F 24 38.8 153
6 F 26 62.0 174
7 F 44 44.2 145
8 M 19 45.6 168
9 F 20 44.0 161
10 F 28 41.0 160
mean 24 43.8 160
23 278 no
20 132 no
22 402 yes
16 1457 yes
15 305 yes
14 103 no
14 5 no
10 792 yes
14 172 no
23 10 no
17 366
C-N score Chrispin-Norman score; atopic specific IgE against inhalative allergens.
CF was established by typical clinical manifesta-
tions of the disease and confirmed by positive
sweat tests (sweat sodium concentration above
70mmol/1). In all patients, chronic Pseudomonas
aeruginosa infection was demonstrated by repeti-
tive positive sputum cultures. Four of the ten
patients (nos. 3, 4, 5 and 8) were atopic, on the
basis of proof of specific IgE against common
inhalative allergens. Total IgE of all patients
ranged from 5kU/1 to 1457kU/1 (mean 363.2
kU/1). Informed written consent was given by all
patients or their parents. Antibiotic treatment was
chosen according to their antibiotic resistance
pattern: seven patients received a combination of
ceftazidime and tobramycin; two patients
received imipenem and tobramycin; and one
patient received ticarcillin and clavulanic acid.
Study design: Patients were admitted to hospital
in a cross-over design both for 14 days of intra-
venous antibiotic treatment against Pseudomonas
aeruginosa
9 and (4 to 6 weeks before or after)
for the same period without antibiotic treatment.
Therefore, each patient seeeed as their own
control. Time of admittance was chosen when
patients were free of acute exacerbations. During
both hospitalizations, usual conservative treat-
ment, such as intensive physiotherapy, inhalation
therapy etc., was performed identically. Blood
and sputum samples were collected in the
morning of days 1, 3, 5, 8, 10, 12 and 15
between 08:00 and 09:00. Lung function tests
were obtained on the same days.
Methods: The clinical severity of CF was assessed
by the Shwachman-Kulczycki score,m modified
by omitting the chest X-ray evaluation. The
highest possible score was therefore 75 points.
Chest X-rays were assessed by Chrispin-Norman
score. Pulmonary function tests were per-
formed in a whole-body plethysmograph (E.
Jaeger, Wrzburg, Germany). A sweat test was
Table 2. Comparison of clinical and laboratory data before
antibiotic treatment (AB) and control phase (Co) at day
AB Co /value
S-K score 47.5 49.5 n.s.
FEV1 (% pred.) 37 38 n.s.
CRP (mg/ml) 12.2 10.0 n.s.
Bacteria/ml 105-106 106-10 < 0.02
MPO (lg/ml) 238 315 n.s.
Neutrophils/nl 6.4 6.8 n.s.
ECP (lg/ml) 12.5 13.8 n.s.
Eosinophils/nl 0.00 0.15 n.s.
Numbers represent median values, n.s. not significant.
performed by quantitative pilocarpine ionto-
phoresis.
Serum was prepared according to guidelines
published recently, and was stored at -20C
until analysed. First morning sputum samples
were diluted 1:1 with phosphate-buffered saline
(PBS). After mixing, I mg of DNase (Sigma, Dei-
senhofen, Germany) and 100ml acetylcysteine
was added. After vortexing, incubation was per-
formed at 37C for 30 to 60 min until complete
liquifaction. Subsequently, samples were cen-
trifuged for 10 min at 1 000 x g. The super-
natants were stored at -80C until analysis.
Eosinophil cationic proteins (ECP) and myelo-
peroxidase (MPO) were determined from serum
and sputum supernatants by double antibody
radioimmunoassay (Kabi Pharmacia, Uppsala,
Sweden).2- Sputum supernatants were diluted
1:100 before analysis.
Leucocyte counts were determined from peri-
pheral EDTA-blood using a Coulter counter
(Coulter Electronics, Krefeld, Germany). Eosino-
phil and neutrophil counts were calculated by
differential blood cell count. C-reactive protein
was analysed by nephelometry (Behringwerke,
Marburg, Germany) using routine methods. Total
and specific IgE was determined by solid phase
immunoassay, using the ’Pharmacia CAP System’
(Kabi Pharmacia, Uppsala, Sweden).
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Statistical analysis: For statistical analysis, the (6.2- 13.0mg/1)on day 1 to 11.4mg/1 (5.0-
Wilcoxon matched-pairs signed rank and the 17.3 mg/1) on day 12.
Spearman correlation tests were used. A value of Lung function (assessed by forced expiratory
p < 0.05 was considered significant. Original data volume in 1 s (FEV1) showed a tendency to
are given as medians and quartiles, increase during antibiotic treatment (from 37%
of the predicted value on day 1 to 39% on day
12), while in the control phase there was a tend-
Reu ency to decrease (from 38% of the predicted
value on day 1 to 32% on day 12) (Table 3).
Clinical parameters: Modified Shwachman- These results failed to reach significance. How-
Kulczycki scores improved significantly during ever, comparison of the antibiotic treatment and
antibiotic treatment from 47.5 on day 1 to 54.5 the control phase revealed a statistically signifi-
on day 12 (p < 0.008, Fig. 1A). In the control cant difference for FEV on day 12 (p < 0.03).
phase there were no statistically significant differ-
ences: 49.5 on day 1 to 50.5 on day 12. Compar-
ison of antibiotic treatment and control phases
revealed a statistically significant difference on
day 12 (p < 0.05, Fig. 1a).
CRP decreased significantly during antibiotic
treatment from 12.2 mg/1 (4.9 23.8 mg/1) on
day 1 to 6.2mg/1 (4.0-7.4mg/1) on day 12
(p < 0.05, Fig. 1B). In the control phase no sig-
nificant changes could be noted: 10.0mg/1
o 80 A
" 70 I-p < 0"00S-’l
N 60
l
e 4tl
-
day day 12
O Antibiotic treatment
p < 0.05
I"-" N-$" "--I
day day 12
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Serum and peripheral blood data: Serum MPO
significantly decreased during antibiotic treatment
from 2381.tg/1 on day 1 to 2281.tg/1 on day 5
(p < 0.04) and 175 l.tg/1 on day 12 (p < 0.006,
Table 3, Fig. 2A). In the control phase, no sig-
nifican changes in serum MPO could be noted:
315btg/1 on day 1, 246btg/1 on day 5, and
2621.tg/1 on day 12 (Table 3, Fig. 2A). Com-
parison of the antibiotic treatment and the
control phase revealed a statistically significant
difference on day 12 (p < 0.006).
Peripheral blood neutrophil granulocyte
counts decreased during antibiotic treatment
from 6.4 cells/nl on day i to 6.1 cells/nl on day 5
(p < 0.05) and 4.7 cells/nl on day 12 (p < 0.04,
Table 3, Fig. 2B). In the control phase no
significant changes in neutrophil counts were
seen: 6.8 cells/nl on day 1, 5.8 cells/nl on day 5,
and 8.6 cells/nl on day 12 (Table 3, Fig. 2B).
Serum ECP concentration showed a tendency
to decrease during antibiotic treatment from
median 12.5 lg/1 on day 1 to 9.5 I.tg/1 on day 5
and 8.9btg/1 on day 12, but this failed to reach
significance (Table 3, Fig. 3A). In the control
phase, no changes in serum ECP could be noted:
13.8g/1 on day 1, 12.21.tg/1 on day 5, and
13.6 I.tg/1 on day 12 (Table 3, Fig. 3A). Peripheral
blood eosinophil counts increased during anti-
biotic treatment (p < 0.03) but not during the
control phase (Table 3, Fig. 3B).
Sputum data: Microbial growth of Pseudomonas
aeruginosa in sputum did not show a significant
decrease both during the antibiotic treatment
and the control phase (Table 3). In general,
sputum concentrations of MPO and ECP were
500- to 1 000-fold higher than in serum (Table
4). There was no statistically significant correla-
tion between serum and sputum MPO or
between serum and sputum ECP concentration.
FIG. 1. Modified Shwachman-Kulczycki score (A) and C-reactive Neither MPO nor ECP showed a significant varia- protein (B) on day and day 12 during antibiotic treatment and
control phase. Columns indicate median, bars indicate 25 and tion over time during antibiotic treatment or the
75 percentiles, control phase.
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FIG. 2. Serum MPO concentration (A) and peripheral blood neut-
rophil granulocyte counts (B) during antibiotic treatment and
control phase. Columns indicate median, bars indicate 25 and
75 percentiles.
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FIG. 3. Serum ECP concentration (A) and peripheral blood eosin-
ophil counts (B) during antibiotic treatment and control phase.
Columns indicate median, bars indicate 25 and 75 percentiles.
Discussion
Originally, a placebo-controlled design was
intended and the present study was started in
this manner. However, after two patients suffered
from pulmonary exacerbations during a placebo
’treatment’, the study was continued as an intra-
individual cross-over design (each patient serving
as its own control). Conditions during the anti-
biotic treatment were completely comparable
(e.g., in terms of physiotherapy, inhalation
therapy, dietetic intervention) with those during
the control phase, with the exception of the
intravenous treatment.
The reason for choosing a control-phase in
addition to antibiotic treatment was the possible
bias of the admission to hospital, which may
improve a patient’s well-being by intensified
basic therapy. In order to minimize observer
bias, the investigator of the study was not the
physician responsible for the care of the patients
on the ward.
In order to study the monitoring character of
the parameters investigated, blood was sampled
Table 4. MPO and ECP concentrations in sputum during antibiotic treatment (AB) and control phase (Co)
Sputum day day 5 day 12
MPO AB 105.8 (44.4 176.1) 69.3 (31.0 148.6) 103.0 (47.8 150.2)
(mg/I) Co 205.4 (106.2 234.8) 162.6 (97.0 213.1) 163.9 (103.3 224.9)
ECP AS 4.3 (2.0- 5.8) 1.6 (1.0 7.9) 2.6 (2.0 6.5)
(mg/I) Co 4.3 (2.9 7.3) 3.9 (1.9 5.1) 4.2 (1.6 6.9)
Numbers represent median values; in brackets: 25 and 75 percentile. Differences between day of antibiotic
treatment and day of control phase were not statistically significant for any of the investigated parameters.
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on 7 days during the antibiotic treatment and impact of antibiotic treatment on serum MPO
control phases. All data points of each individual concentration.
were analysed; however, three time-points (day 1, Concerning the role of the eosinophil and its
5 and 12) are given in the figures and tables to granule proteins in CF, there is little data in the
avoid unclear presentation and because complete literature: Koller et al. found increased serum
data did not add any information to those pre- levels of ECP in most of their 42 CF patients.
7 In
sented, contrast, only three of our ten CF patients had
Lung function parameters, such as FEV1, did an increased serum ECP concentration (> 20tg/
not differ significantly on day 1 either before 1), although CF in our patients was more severe
starting antibiotic treatment (median 37% of pre- than in the Austrian group. The four atopic
dicted) or control phase (median 38% of pre- patients did not show a different pattern from
-dicted). The same was true for modified the non-atopic patients.
Shwachman-Kulczycki scores: median 47.5 Conflicting results continue, e.g., Azzawi et al.
points for day 1 of antibiotic treatment and 49.5 observed an increased number of EG2 positive
points for day 1 of the control phase. Therefore, cells in post-mortem lungs of CF ,patients, but
starting points for both phases were comparable normal numbers of eosinophils. This dis-
(Table 2). crepancy may be interpreted as an increased
FEV1 values showed an improvement at the propensity of the eosinophils to release their
end of antibiotic treatment compared with the granule proteins as suggested by Koller.7 Serum
control phase. This effect of antibiotic treatment ECP levels showed a tendency to decrease under
has been observed by other authors.6’8’9 The antibiotic treatment, but this failed to reach sig-
improvement of lung function was paralleled by nificance in either the Austrian study (elevated
other parameters such as the Shwachman-Kulc- levels of ECP in 90% of their patients), or in our
zycki score, serum MPO concentration and CRP. investigation (30% of patients had an increased
It seems that this positive effect is even seen at a ECP concentration).
time-point where patients did not suffer from Peripheral blood eosinophils increased during
clinical exacerbations, antibiotic treatment in our study. Because of the
CRP reflects the pulmonary inflammatory state low absolute numbers of eosinophils, our obser-
in chronically infected CF patients, is increased vation is probably not of clinical relevance,
during pulmonary exacerbations, and decreases despite the statistical significance. Further studies
during antibiotic treatment,
6 but it is not a reli- are needed to elucidate the role of the eosino-
able indicator of intermittent bacterial coloniza- phil for airway inflammation in CF.
tion in early lung disease,i Very high In the local compartment, the sputum, MPO as
concentrations of CRP are seen days and weeks well as ECP concentrations, were 500- to 1 000-
before death.
2 However, in bronchoalveolar fold higher than in serum. This reflects their role
lavage (BAL), the degree of airway obstruction, in local inflammatory lung injury. However, the
neutrophil elastase activity, myeloperoxidase failure to reduce sputum concentrations of these
activity, or total neutrophils did not correlate highly toxic proteins by intravenous antibiotic
with the density of P. aeruginosa (CFU/ml)or therapy makes additional forms of treatment
total pathogen burden in BAL fluid.
22 necessary. The Austrian group found a significant
MPO, as a neutrophil inflammatory mediator, correlation between serum and sputum MPO and
is not only increased in chronically infected ECP concentration.7 Our data does not confirm
cystic fibrosis patients, but also in other dis- this. The inherent problem lies in the non-
eases. It was found increased in BAL of idio- homogenous composition of sputum, depending
pathic pulmonary fibrosis,
23 transiently on local factors of the lung region from which it
increased in BAL during recovery from airway was sampled. In our view, sputum measurements
hyperresponsiveness
24 and increased in BAL do not seem to be a reliable parameter for
from some patients with bronchial asthma.25 monitoring inflammatory changes in CF.
Furthermore, the release of MPO from neut- From our data we conclude that: (1) measure-
rophils of patients with asthma was somewhat ments of MPO, neutrophils and CRP in periph-
higher than in controls.
26 Serum MPO con- eral blood correlate with clinical parameters such
centration was even suggested to be a good as the modified Shwachman-Kulczycki score; (2)
indicator of exposure to noxious agents neutrophils and MPO seem to reflect inflamma-
causing respiratory disorders, such as in ’sick tory changes induced by antibiotic treatment; (3)
building syndrome’,
iv From this study, there is eosinophils may. play a role in CF by an
evidence for a role of MPO in chronic lung enhanced ’releasability’; and (4) sputum mea-
inflammation in CF, as shown by elevated surements of mediators of inflammation cannot
blood levels in some patients, as well as the be recommended.
Mediators of Inflammation Vol 4 1995 287B. Niggemann et al.
References
1. Bruce MC, Poncz L, Klinger JD, Stem RC, Tomashefski JF jr, Dearborn
DG. Biochemical and pathologic evidence for proteolytic destruction of
lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985; 132=
529-535.
2. Suter S, Schaad LIB, Roux L, Nydegger UE, Waldvogel FA. Granulocyte
neutral proteases and Pseudomonas elastase as possible causes of airway
damage in patients with cystic fibrosis. J Infect Dis 1984; 4: 523-531.
3. Tetley TD. Proteinase imbalance: its role in lung disease. Thorax 1993;
48: 560-565.
4. Elborn JS, Cordon SM, Shale DJ. Host inflammatory responses to first
isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis.
Pediatr Pulmono11993; 15: 287-291.
5. Cantin A, Woods DE. Protection by antibiotics against myeloperoxidase-
dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 1993;
91: 38-45.
6. Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ.
Inflammatory markers in cystic fibrosis. Resp Med 1991; 85: 139-145.
7. Koller DY, G6tz M, Eichler I, Urbanek R. Eosinophilic activation in cystic
fibrosis. Thorax 1994; 49: 496-499.
8. Azzawi M, Johnston PW, Majumdar S, Kay AB, Jeffrey PK. T lymphocytes
and activated eosinophils in airway mucosa in fatal asthma and cystic
fibrosis. Am Rev Respir Dis 1992; 145: 1477-1482.
9. Hoiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibrosis
and its management. Thorax 1990; 45: 881-884.
10. Shwachman H, Kulczycki LL. Long-term study of one hundred and five
patients with cystic fibrosis. AmJDis Child 1958; 96: 6-15.
11. Chrispin AR, Norman AP. The systematic evaluation of the chest radio-
graph in cystic fibrosis. Pediat Radio11974; 2: 101-106.
12. Peterson CGB, Enander I, Nystrand J, Anderson AS, Nilson L, Venge P.
Radioimmunoassay of human eosinophfl cationic protein (ECP) by an
improved method. Establishment of normal values in serum and turnover
in viva Clin Exp Allergy 1991; 21: 561-567.
13. Venge P, Roxin LE, Olsson I. Radioimmunoassay of human eosinophil
cationic protein. BrJ Haemato11977; 37: 331-335.
14. Enander I, Andersson AS, Peterson C, Venge P. A new radio-immuno-
assay to determine human neutrophilic myeloperoxidase (MPO). Scbweiz
Med Wschr 1991; 121(Suppl 40): 38.
15. Venge P, Stromberg A, Brocanier JH, Roxin LE, Olsson I. Neutrophil and
eosinophil granulocytes in bacterial infection: sequential studies of
cellular and serum levels of granule proteins. Br J Haematol 1978; 38;
475-483.
16. Olofsson T, Olsson I, Venge P, Elgefors B. Serum myeloperoxidase and
lactoferrin in neutropenia. ScandJ Haemato11977; 18: 73-88.
17. Axn R, Drevin H, Kober A, Yman L. A new laboratory diagnostic system
applied to allergy testing. New Engl Reg Allergy Proc 1988; 9: 503.
18. Regelmann WE, Elliott GR, Warwick wJ, Clawson CC. Reduction of
sputum Pseudomonas aerugonisa density by antibiotics improves lung
function in cystic fibrosis more than bronchodilators and chest phy-
siotherapy alone. Am Rev Respir Dis 1990; 141: 914-921.
19. Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis-M611er A, Koch C.
Immediate and prolonged clinical efficacy of ceftazidime versus ceftazi-
dime plus tobramycin in chronic Pseudomonas aeruginosa infection in
cystic fibrosis. ScandJInfectDis 1986; 18: 133-137.
20. Watldn SL, Elbom JS, Cordon SM, Hiller EJ, Shale DJ. C-reactive protein is
not a useful indicator of intermittent bacterial colonization in early lung
disease of patients with cystic fibrosis. Pediatr Pulmono11994; 17: 6-10.
21. Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ. The host
inflammatory response prior to death in patients with cystic fibrosis and
chronic Pseudomonas aeruginosa infection. Resp Med 1993; 87: 603-
6O7.
22. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pul-
monary dysfunction in cystic fibrosis. J Lab Clin Med 1993; 121: 654-661.
23. Hiillgren R, Bjermer L, Lundgren R, Venge P. The eosinophil component
of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989;
139: 373-377.
24. Gundel RH, Wegner CD, Letts LG. The onset and recovery from airway
responsiveness: relationship with inflammatory infiltrates and release of
cytotoxic granule proteins. Clin Exp Allergy 1992; 22: 303-308.
25. Bousquet J, Chanez P, Lacoste JY, et al. Indirect evidence of bronchial
inflammation assessed by titration of inflammatory mediators in Bal fluid
of patients with asthma. JAllergy Clin Immuno11991; 88: 649-660.
26. Carlson M, Hansson L, Peterson C, Stalenheim G, Yenge P. Secretion of
granule proteins from eosinophils and neutrophils is increased in asthma.
JAllergy Clin Immuno11991; 87.- 27-33.
27. Metso T, BjOrksten F, Kilpi6 K, Kiviranta K, Haa_htela T. Serum myeloper-
oxidase and sick building syndrome. Lancet 1993; 342: 113-114.
Received 9 March 1995;
accepted in revised form 1 May 1995
288 Mediators of Inflammation Vol 4. 1995